MedTrace Logo

Atacand (Candesartan) Real Life Study

NCT00620178 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 14000

Last updated 2010-12-02

No results posted yet for this study

Summary

This study is a Swedish historical cohort study in patients prescribed Atacand or Cozaar for hypertension by selected primary care centres. Data will be extracted anonymously from electronic medical records. In addition, data regarding morbidity and mortality will be collected by merging the cohort with the following national registries: the Hospital Discharge Register (Slutenvårdsregistret), the Cause of Death Register and the Heart Intensive Care Admission (RIKS-HIA)

Conditions

Interventions

DRUG

Candesartan Cilexetil

oral once daily dose

DRUG

Losartan

once daily oral dose

Sponsors & Collaborators

Principal Investigators

  • Jan Stålhammar, MD · Eriksbergs vårdcentral

Eligibility

Min Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-03-31
Primary Completion
2009-02-28
Completion
2009-02-28

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00620178 on ClinicalTrials.gov